42955-22-6

Basic information

• Product Name: 6-Ethoxypyridine-2-carboxylic acid
• Synonyms: 6-Ethoxypyridine-2-carboxylic acid;6-Ethoxypicolinic acid;6-Ethoxypicolinic acid, 2-Carboxy-6-(ethoxycarbonyl)pyridine
• CAS NO: 42955-22-6
• Molecular Formula: C₈H₉NO₃
• Molecular Weight: 167.16196
• Product Categories: Pyridine series;Carboxylic Acids;Pyridines;Carboxylic Acids
• Mol File: 42955-22-6.mol

Chemical Properties

• Boiling Point: 310.6°Cat760mmHg
• Flash Point: 141.6°C
• Appearance: /
• Density: 1.231g/cm³
• Vapor Pressure: 0.000256mmHg at 25°C
• Refractive Index: 1.54
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 3.54±0.10(Predicted)
• CAS DataBase Reference: 6-Ethoxypyridine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Ethoxypyridine-2-carboxylic acid(42955-22-6)
• EPA Substance Registry System: 6-Ethoxypyridine-2-carboxylic acid(42955-22-6)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 42955-22-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Ethoxypyridine-2-carboxylic acid is used as a building block for the synthesis of various drugs and pharmaceutical products, leveraging its chemical structure to create new therapeutic agents.
Used in Drug Discovery:
6-Ethoxypyridine-2-carboxylic acid is used as a drug discovery tool due to its potential biological activity, which is being studied to identify new therapeutic targets and develop novel pharmaceuticals.
Used in Organic Synthesis:
6-Ethoxypyridine-2-carboxylic acid is used as a reagent in organic synthesis, contributing to the creation of a wide range of chemical compounds for various applications.
Used in Coordination Chemistry:
6-Ethoxypyridine-2-carboxylic acid is used as a ligand in coordination chemistry, playing a crucial role in the formation and stabilization of metal complexes, which have applications in areas such as catalysis and materials science.

InChI:InChI=1/C8H9NO3/c1-2-12-7-5-3-4-6(9-7)8(10)11/h3-5H,2H2,1H3,(H,10,11)

Upstream product

• 890655-74-0 ethyl 6-ethoxypicolinate 
• 19621-92-2 6-Hydroxypicolinic acid 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol "APLNR"). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.